SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell Lymphoma.

Nodal PTCLs are a rare subset of non-Hodgkin lymphomas that are clinically and biologically heterogenous and have poor outcomes. There have been several attempts to improve upon existing frontline therapies, many of which have shown improvement or signals of improvement in outcomes, such as adding etoposide and brentuximab vedotin to CHOP-based chemotherapy, and consolidative autologous stem-cell transplant in first remission. Though there has some been some success, many studied regimens have either failed to improve outcomes and/or have increased toxicity. However, many of these studies have unveiled important findings regarding the underlying biology of PTCLs, thereby leading to the design of more precise and biology-driven clinical trials. Additionally, attempts are being made to better risk stratify patients and identify strategies to best monitor patients following frontline treatment. Though many studies are ongoing, at this time better treatment strategies for frontline PTCL are needed.